QCC-374
- Generic Name
- QCC-374
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02939599
- Locations
- 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom
Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients
Phase 2
Terminated
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Drug: Placebo Matching
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 8
- Registration Number
- NCT02927366
- Locations
- 🇬🇧
Novartis Investigative Site, Cambridge, Cambridgeshire, United Kingdom
A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374
- First Posted Date
- 2014-09-22
- Last Posted Date
- 2016-03-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02245828
- Locations
- 🇬🇧
Novartis Investigative Site, Mid Glamorgan, Wales, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath